# Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

Source: https://onco.cc/trials/nct06462183/  
OnCo record `nct06462183` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of RGT-61159 run by Rgenta Therapeutics Inc, active and no longer recruiting.

## Summary

Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) is a phase 1 interventional study registered as NCT06462183 by Rgenta Therapeutics Inc, with 105 participants planned, started 2024-08-19. Conditions recorded: Adenoid Cystic Carcinoma and Colorectal Cancer. Interventions recorded: RGT-61159 and lenvatinib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06462183
- Phase: 1
- Setting: A Phase 1a/1b, First-in-human, Multicenter Study to Assess the Efficacy and Safety of RGT-61159 for Treatment of Patients With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
- Sponsor: Rgenta Therapeutics Inc
- Enrolled: 105

## Sources

- ClinicalTrials.gov NCT06462183: https://clinicaltrials.gov/study/NCT06462183

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Salivary gland cancers](https://onco.cc/cancers/salivary-gland/)
- drugs: [RGT-61159](https://onco.cc/drugs/rgt-61159/)
- companies: [Rgenta Therapeutics](https://onco.cc/companies/rgenta-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06462183.json